Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
about
Novel therapeutics for Alzheimer's disease: an updateCholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's diseaseGRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability.Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimenMedicinal chemistry approaches for the treatment and prevention of Alzheimer's disease.Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Frontiers in Alzheimer's disease therapeutics.Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.Antioxidant approaches for the treatment of Alzheimer's disease.Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?Recall and recognition of verbal paired associates in early Alzheimer's disease.Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.Donepezil in the treatment of patients with Alzheimer's disease.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Thinking Outside the Box in Alzheimer Disease Treatment
P2860
Q24620383-300D8161-297D-4A6D-9273-A5951CE86BB8Q28287090-4999A305-8C9F-4754-97EC-DE95BF05920EQ33363144-522A2BEB-7D16-4002-9FD0-9F528B298847Q34655353-F0CA602D-9D3B-426E-B37F-90F38F0CC8B6Q34993154-BA1383B3-5476-458C-B06F-C52AFB5AC324Q35066849-3B4B38CF-03B3-469F-B29D-983BB7F82793Q35086876-7367A57C-A7FC-4177-8569-1250957E1457Q36817040-ED36A9F2-233A-44FE-92FA-6E984A0CC62DQ36846711-4795AEB4-C5F4-49CC-BEC4-B2F8AE5A8D04Q37405505-BA024343-F856-45CE-8405-72FDBFF8DD25Q37461883-9407DD1A-C506-4D19-9297-8589B1EA3C84Q37768449-664E72A4-D01C-45B0-85A6-145422BD3809Q38132755-94B89A72-07FD-48D9-A8C9-067A690FE7BAQ38389343-6A49A58F-5A58-4CFF-B242-1F7E812CF588Q38962796-0C346FFB-22A2-4E71-B065-DE8F2E185139Q41718243-C812AB8B-D753-45DC-A013-7A714898126FQ43265594-173A83CC-86E7-4B8D-97E2-60DFBF2F8763Q48167336-10070732-8428-4E9F-8439-7E665CAF087AQ57341342-DF46CC64-90F3-4A64-975F-516AE498DC2D
P2860
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@ast
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@en
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@nl
type
label
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@ast
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@en
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@nl
prefLabel
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@ast
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@en
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@nl
P1433
P1476
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
@en
P2093
Giacobini E
P356
10.2165/00023210-200115020-00001
P577
2001-01-01T00:00:00Z
P6179
1046226273